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Improved Survival of Patients With End-Stage
Heart Failure Listed for Heart Transplantation
Analysis of Organ Procurement and Transplantation Network/
U.S. United Network of Organ Sharing Data, 1990 to 2005
Katherine Lietz, MD, PHD, Leslie W. Miller, MD
Washington, DC
Objectives We sought to investigate the actual survival of patients with end-stage heart failure listed for heart transplanta-
tion (HT) in the U.S.
Background The United Network of Organ Sharing (UNOS) reported that the mortality rates on the U.S. HT waiting list have
been gradually declining. This suggests that the survival of these patients may have improved.
Methods The survival censored on the day of HT or removal from the waiting list was calculated for 18,004 UNOS status 1
and 30,978 status 2 candidates listed in eras I (1990 to 1994), II (1995 to 1999), and III (2000 to 2005) in the
U.S. The Cox proportional model was employed for multivariable analysis.
Results The 1-year survival on the HT waiting list improved from 49.5% to 69.0% for status 1 and from 81.8% to 89.4%
for status 2 candidates between eras I and III. The predictors of death within 2 months from listing of status 1
candidates included UNOS status 1A, mechanical ventilation, inotropic and intra-aortic balloon pump support,
pulmonary capillary wedge pressure 20 mm Hg and serum creatinine 1.5 mg/dl, failed HT, valvular cardio-
myopathy, age 60 years, Caucasian ethnicity, and weight 70 kg, as well as the lack of intracardiac
cardioverter-defibrillator on the day of listing.
Conclusions Survival of HT candidates on the waiting list has significantly improved. Survival of status 1 candidates continues
to depend on urgent HT. Predictors of 2-month mortality may help identify status 1 candidates who warrant the
highest priority for HT and/or mechanical circulatory support. The 1-year survival of status 2 candidates ap-
proaches outcomes of HT, thus raising the question of whether early listing of some of these patients is justified.
(J Am Coll Cardiol 2007;50:1282–90) © 2007 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.04.099s
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1eart transplantation (HT) is the only therapy proven to
rovide the greatest survival benefit in patients with end-
tage heart failure (1,2). However, liberal expansion of HT
See page 1291
as been limited by a continued shortage of available
onor organs. During the last 2 decades, the number of
atients awaiting HT reached its historical high when
,602 patients were listed in 1998 and only 2,211
ransplants were performed (3). The continued disparity
etween the number of HT candidates and the limited
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ccepted April 30, 2007.upply of donor organs was associated with longer time
pent on the national waiting list by an average HT
andidate. At the end of 2005, 48% of HT candidates had
pent more than 2 years on the waiting list, compared
ith 17% in 1993 (4).
According to the recent report of the United Network
f Organ Sharing (UNOS) (3), the increasing length of
ime spent by an average candidate on HT waiting list did
ot result from a larger number of listed candidates or
onger waiting times for HT. In contrary, the number of
ew candidates decreased from 3,877 to 2,833 and the
edian waiting time for HT shortened from 354 to 130
ays between 1996 and 2005. These observations suggest
hat the survival of patients referred for HT may have
ubstantially improved. Indeed, since the 1990s, the
ortality rates on HT waiting list decreased from 227.4
er 1,000 patient-years at risk for candidates listed in
996, to the historically lowest level of 152.3 noted for
hose listed in 2005 (3).
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September 25, 2007:1282–90 Survival of Candidates for Heart TransplantationIn this study, we sought to investigate the survival of
8,982 patients with advanced heart failure who were listed
or HT between the years 1990 and 2005 in the U.S. The
im of the study was 2-fold: 1) to describe changes in the
ctual survival on the HT waiting list of UNOS status 1 and
candidates throughout the study period; and 2) to identify
redictors of death within 2 months from listing, which would
elp identify status 1 and 2 HT candidates at the highest
riority for allocation and/or consideration for mechanical
irculatory support (MCS).
atients and Methods
tudy population. Forty-nine thousand seven hundred
hirty-nine adult patients (older than 18 years) were listed
or HT between January 1, 1990, and January, 1 2006 in the
.S. This included 18,004 patients initially listed as UNOS
tatus 1 and 30,978 patients initially listed as UNOS status
. Seven hundred fifty-seven patients who were initially
isted as inactive or had other status on the day of enroll-
ent on the transplant waiting list were excluded from this
nalysis. The final study sample numbered 48,982 trans-
lant candidates. All patients were followed until death or
he day of the last observation on June 1, 2006.
ata source. Patient data were obtained from the U.S.
overnment-sponsored Scientific Registry of Transplant Re-
ipients. The Registry collects information on all organ trans-
lant recipients and is mandatory in the U.S. All patients were
ollowed from time of enrollment on the HT waiting list until
ransplantation and/or death with the use of data forms
ollected by the Organ Procurement and Transplantation
etwork. Post-transplant information was reported at the end
f the annual follow-up period and at the time of death. The
ate of death after HT was provided by the transplant center,
nd this information was supplemented by data obtained from
he Social Security Administration Death Master File and the
edicare Beneficiary Database provided by the Centers for
edicare andMedicaid Services. Causes of death while on the
aiting list were not reported to the Registry.
edical urgency status. The medical urgency for HT was
ssigned by the transplant physician as UNOS status 1 or
tatus 2 on the day of registration. For the purpose of this
nalysis, the 2-tiered status 1 category (1A and 1B) introduced
fter 1999 (5) was combined into 1 UNOS status 1 category.
he high urgency UNOS status 1 defines candidates who
equire continuous intravenous inotropes, or require MCS
ith intra-aortic balloon pump (IABP), left ventricular assist
evices, total artificial heart, extracorporeal mechanical oxygen-
tion, or mechanical ventilation, have life expectancy 7 days
ithout transplant, or are considered a justified exceptional
ase. Status 2 candidates should meet general criteria for HT as
utlined in the guidelines (2) but do not meet status 1A or 1B
riteria.
linical information. Candidate demographics and the
ost recent assessment of hemodynamics and serum creat- snine were provided on the day of
isting. Mechanical circulatory
upport was defined in this study
s presence of temporary or per-
anent circulatory support devices
n the day of listing, including
ight-, left-, or biventricular sup-
ort devices or total artificial
eart, and did not include IABP
upport or use of extracorporeal
echanical oxygenation. Inotro-
ic support was reported as the
resence or absence of intravenous
notropic drugs on the day of
isting and does not indicate ino-
rope dependence. The informa-
ion whether medical therapy was intensified or device
herapy was introduced after the day of listing, such as
mplantation of intracardiac cardioverter-defibrillator (ICD)
r MCS, was not reported to the Registry.
tatistical analysis. Survival estimates were calculated us-
ng the Kaplan-Meier actuarial survival curves (6). Two
pproaches were used to assess survival of patients awaiting
T. First, we calculated the probability of survival on the
aiting list, as illustrated in Figures 1A and 1B. These
nalyses calculated time from the day when patients were
nitially listed as either UNOS status 1 or status 2 candidates
ntil death on the waiting list. They were censored at the
ime of removal from the waiting list as the result of
ransplantation, worsening or improvement of condition, or
he day of the last observation (June 1, 2006). The second
pproach was to retrospectively describe survival of patients
ho did or did not undergo transplantation during the
ollow-up period, as illustrated in Figures 2A and 2B. In
his case, the survival was calculated from the day when
atients were initially listed as UNOS status 1 or status 2
andidates until death, either on the waiting list for those
ho did not undergo HT or after HT for those who received
transplant. The survival was censored at the time of removal
f patients from the waiting list as the result of worsening or
mprovement of condition or on the day of the last observation
June 1, 2006). Both approaches to survival analysis did not
ccount for change of the UNOS status during the follow-up
eriod, including temporary inactivation of status.
ultivariable analysis. To identify predictors of death
ithin 2 months from the day patients were listed as UNOS
tatus 1 or 2 candidates in the years 2000 to 2005, all
arameters listed in Tables 1 and 2 that correlated by univariate
nalysis with the end point at p  0.15 were entered and
llowed to stay in the multivariable Cox proportional hazards
urvival model at p  0.05 using stepwise selection (7).
ulticollinearity analysis was subsequently performed to con-
rm that the final model was not unduly influenced by
ollinearity between predictors in the model.
Differences between groups were examined with chi-
Abbreviations
and Acronyms
HT  heart transplantation
IABP  intra-aortic balloon
pump
ICD  intracardiac
cardioverter-defibrillator
ICU  intensive care unit
MCS  mechanical
circulatory support
PCWP  pulmonary
capillary wedge pressure
UNOS  United Network of
Organ Sharingquare or Student t tests. Results were considered significant
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Survival of Candidates for Heart Transplantation September 25, 2007:1282–90or p 0.05. Values are reported as mean SD. Data were
nalyzed using the SAS System software version 7.0 (SAS
nstitute, Inc., Cary, North Carolina).
esults
isting trends of HT candidates. As illustrated in Figure 3,
he number of UNOS status 1 candidates enrolled on HT
aiting lists increased from 836 patients in 1990 to 1,159
atients in 2005. During the same period of time, the
Figure 1 The Actuarial Survival on the U.S. Heart
Transplant Waiting List: Years 1990–2005
The actuarial survival on the heart transplant waiting list was calculated for
18,004 United Network of Organ Sharing (UNOS) status 1 candidates (A) and
30,978 UNOS status 2 candidates (B) listed between years 1990 and 2005 in
the U.S. The results were stratified by 3 eras of listing: I (years 1990–1994), II
(years 1995–1999), and III (years 2000–2005), respectively. The analyses
were censored at time of transplantation, removal from the waiting list due to
worsening or improvement of condition, or the day of last observation on June
1, 2006, and did not account for subsequent changes of UNOS status or tem-
porary inactivation of status.umber of patients listed as UNOS status 2 decreased from d,332 patients listed in 1990 to 1,147 patients listed in 2005.
hese trends were associated with an increased proportion
f the listed-to-transplanted HT candidates per calendar
ear from 41% in 1990 to 77% in 2005.
ras of listing and characteristics of HT candidates. The
Figure 2 The Survival of Candidates Who Did and Did Not
Undergo Heart Transplantation: Years 1990–2005
The actuarial survival of patients who did and did not undergo heart transplan-
tation was calculated for 18,004 United Network of Organ Sharing (UNOS) sta-
tus 1 candidates (A) and 30,978 UNOS status 2 candidates (B) listed
between years 1990 and 2005 in the U.S. The results were stratified by 3
eras of listing: I (years 1990–1994), II (years 1995–1999), and III (years
2000–2005), respectively. The survival was calculated from the day of listing
until death on the waiting list for patients who did not undergo transplantation
or death after heart transplantation. The analyses were censored at time of
removal from the waiting list due to worsening or improvement of condition or
the day of last observation on June 1, 2006, and did not account for subse-
quent changes of UNOS status or temporary inactivation of status.emographic characteristics of UNOS status 1 and UNOS
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September 25, 2007:1282–90 Survival of Candidates for Heart Transplantationtatus 2 HT candidates were stratified by the era of listing as
hown in Table 1. Overall, the majority (63.2%) of studied
atients were listed as UNOS Status 2, men (78.2%),
ounger than 60 years of age (80.6%), of Caucasian ethnicity
79.3%), and ABO O blood type (43.2%). The 2 major
tiologies of heart failure included ischemic (50.4%) and
diopathic dilated cardiomyopathy (31.9%). During the
tudy period, there was a significant trend towards increased
nrollment of females, patients of non-Caucasian ethnicity,
atients older than 60 years, patients with nonischemic
ardiomyopathy, and patients with weight 90 kg among
oth UNOS status 1 and 2 candidates, as shown in Table 1.
ras of listing and severity of heart failure in HT
andidates. The clinical and hemodynamic indicators of
everity of heart failure in UNOS status 1 and 2 HT
andidates were stratified by the era of listing, as shown in
able 2.
In the most recent era III, the majority of patients listed
s UNOS status 1 candidates were hospitalized at the time
f listing (82%), including 56% in the intensive care unit
ICU). The majority (71%) required continuous infusion of
notropes or circulatory support with IABP (12%) or MCS
23%). The least-ill group, as judged by the aforementioned
riteria, comprised patients listed in era I. Although 87% of
hem were hospitalized at the time of listing, only 20% were
n the ICU, 14.6% required intravenous inotropes, 3.4%
emographics of UNOS Status 1 and 2 Candidates for Heart Transpo 1994, II  1995 to 1999, and III  2000 to 2005: U.S. Scie ti
Table 1 Demographics of UNOS Status 1 and 2 Candidates forto 1994, II  1995 to 1999, and III  2000 to 2005:
UNOS Status 1
Era I
(n  4,541)
(%)
Era II
(n  6,087)
(%)
Demographics
Male gender 79.2* 76.1
Age 60 yrs 15* 20.4
Caucasian ethnicity 81.5* 77.5*
African American ethnicity 11.8* 14.6*
Body weight 90 kg 14.0* 21.1*
ABO blood type
O group 41.7 42.8
A group 41.8* 40.2†
B group 12.1† 12.7
AB group 4.3 4.2
Etiology of heart disease
Ischemic heart disease 56.7* 48.7*
Idiopathic CM 25.8* 33.3
Secondary dilated CM‡ 4.0* 7.0*
Failed heart transplant 3.5 3.6
Valvular CM 2.1 2.5
Congenital heart disease 0.8* 1.8
Restrictive CM 0.9* 1.3
Hypertrophic CM 0.3* 0.6*
Other unclassified 6.0* 1.2†
tatistical difference when compared to the most recent era III: *p  0.001, †p  0.05. ‡Secon
yocarditis and alcoholic, viral, and other unspecified causes.
CM  cardiomyopathy; UNOS  United Network of Organ Sharing.ere on IABP support, and 8.4% were on MCS. HIn contrast, the vast majority of those listed as UNOS
tatus 2 candidates were not hospitalized at the time of
isting (85% to 87% throughout the eras I and III) and did
ot require inotropic or device circulatory support. There
ere no major differences across eras in terms of the clinical
everity of heart failure in this group.
utcomes of UNOS status 1 candidates. Overall, the
ajority (67%) of 18,004 UNOS status 1 candidates listed
rom 1990 to 2005 underwent HT after the median waiting
ime of 2.1 months, 21% died on the waiting list, and the
emaining 12% of patients were removed from transplant
aiting lists because of improvement (2.5%), deterioration
f condition (3.2%), or other reasons (4.6%) or were
ngoing at the time of study (1.7%). At the end of the
ollow-up period, 4.6% of candidates were downgraded to
NOS status 2, and 13.3% were made temporarily inactive.
ne-year outcomes on the waiting list for UNOS status 1
andidates stratified by the eras of listing are shown in Table 3.
ras of listing and HT in UNOS status 1 candidates.
he calculated probability of HT within 1 year from listing
f UNOS status 1 candidates censored at the time of
emoval from the waiting list because of death or other
easons remained nearly unchanged throughout the study
eriod: 86.8%, 84.6%, and 83.5% in eras I, II, and III,
espectively (p 0.001). The corresponding median time to
tion Across Eras: I  1990g stry for Transplant Recipients (n  48,982)
t Transplantation Across Eras: I  1990
Scientific Registry for Transplant Recipients (n  48,982)
UNOS Status 2
Era III
7,376)
(%)
Era I
(n  11,904)
(%)
Era II
(n  10,843)
(%)
Era III
(n  8,231)
(%)
75.4 81.0* 78.3† 76.5
21.4 15.2* 21.1* 23
71.1 83.5* 81.7* 77.6
17.9 11.1* 11.6* 13.6
26.5 23.3* 29.4* 34.3
43.2 43.2 44 43.4
38.2 40.6 40.5 40.5
13.8 12.1 11.4 12.2
4.7 4.1 4.1 3.9
44.6 56* 49.4* 47
34.0 30 35.5* 31
9.2 3.8* 4.9* 7.2
3.7 1.9* 2.8† 3.5
2.6 2.7 2.6 2.9
1.5 1.3* 1.9* 2.7
1.5 0.9* 1.3† 1.8
1.2 0.4* 1* 1.9
1.6 3.4* 0.7* 1.9
uses of dilated cardiomyopathy include the following: adriamycin-induced, post-partum, familial,lantafic Re
Hear
U.S.
(n 
dary caT has also remained stable, despite the initial increase
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o 2.14 months in era III (p  0.001).
ras of listing and survival on the waiting list of UNOS
tatus 1 candidates. The 1-year survival on the waiting list
f UNOS status 1 candidates censored at the time of
emoval from the waiting list due to transplant or other
easons increased from 49.5% to 63.3% to 69.0% in eras I,
I, and III (p  0.001), as illustrated in Figure 2A. The
-year survival of UNOS status 1 patients who remained on
Figure 3 The Number of UNOS Status 1 and 2 Heart Transplant
The number of the United Network of Organ Sharing (UNOS) status 1 candidates l
1,159 patients in year 2005. During the same period of time the number of patien
1,147 patients listed in year 2005. These trends were associated with an increas
year from 41% in year 1990 to 77% in year 2005 (red line).
everity of Heart Failure in UNOS Status 1 and 2 Candidates for Heo 1994, II  1995 to 1999, and III  2000 to 2005: U.S. Scienti
Table 2 Severity of Heart Failure in UNOS Status 1 and 2 Candto 1994, II  1995 to 1999, and III  2000 to 2005:
UNOS Status 1
Era I
(n  4,541)
(%)
Era II
(n  6,087)
(%)
Hemodynamics and renal function
MPAP 30 mm Hg — 44.8*†
PCWP 20 mm Hg — 62.0*†
SPA 50 mm Hg — 64.2*†
Serum creatinine 1.5 mg/dl — —
Hospitalization on the day of listing
Hospitalized in ICU 19.8* 80.8*
Hospitalized, not in ICU 67.2* 10.0*
Not hospitalized 13.0* 9.1*
Medical and device treatment
ICD — 15.0‡
Intravenous inotropes 3.1* 13.8*
Mechanical ventilation 14.3* 17.0*
IABP 3.4* 14.5*
MCS 8.4* 19.1*
ECMO 0.1* 1.0
tatistical difference when compared to the most recent era III, *p  0.001, †missing data 15%
—  data not available; ECMO  extracorporeal mechanical oxygenation; IABP  intra-aortic
CSmechanical circulatory support; MPAPmean pulmonary artery pressure; PCWP pulmon
haring.he waiting list and did not undergo HT improved from
6.7% to 28.5% to 40.2% of those listed in eras I, II, and III
p 0.001), whereas for those who underwent HT, survival
rom the day of listing until death after HT increased from
4.5% to 85.2% to 86.7% of those listed in eras I, II, and III
p  0.001), as illustrated in Figure 3A.
redictors of death within 2 months of listing in UNOS
tatus 1 candidates. The results of multivariable analysis of
isk factors for death on the waiting list within 2 months in
didates Listed in the U.S.: Years 1990–2005
or heart transplantation in the U.S. increased from 836 patients in year 1990, to
ed as UNOS status 2 decreased from 2,332 patients listed in year 1990 to
portion of the listed-to-transplanted heart transplant candidates per calendar
ransplantation Across Eras: I  1990gistry for Tra splant Recipients (n  48,982)
s for Heart Transplantation Across Eras: I  1990
Scientific Registry for Transplant Recipients (n  48,982)
UNOS Status 2
Era III
(n  7,376)
(%)
Era I
(n  11,904)
(%)
Era II
(n  10,843)
(%)
Era III
(n  8,231)
(%)
36† — 49.5*† 35.3†
52.9† — 50.1*† 36.8†
54.6† — 35.7*† 22.7†
29.5‡ — — 21.0‡
55.8 5.7 6.4 5.1
26.4 7.8 8.7 7.7
17.8 86.5 84.9 87.1
40.7‡ — 18.3‡ 46.7‡
11.3 1.4* 9.3* 7.4
11.3 0.1* 0.5§ 0.8
12.1 0.1* 0.5§ 0.7
22.8 1.1* 2.2 2.0
1.1 0 0 0
sing data 5%, §p  0.05.
rpulsation balloon pump; ICD  implantable cardioverter-defibrillator; ICU  intensive care unit;
illary wedge pressure; SPA systolic pulmonary artery pressure; UNOS United Network of OrganCan
isted f
ts list
ed proart Tfic Re
idate
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September 25, 2007:1282–90 Survival of Candidates for Heart Transplantation,451 UNOS status 1 candidates listed in the years 2000 to
005 are shown in Table 4. Twenty-six percent of 7,376
NOS status 1 candidates were excluded from this analysis
ecause of a lack of information on the presence of ICD on
he day of listing and assessment of hemodynamics and
enal function. The following risk factors were identified as
ndependent predictors of early death: mechanical ventila-
ion, failed HT, valvular cardiomyopathy, UNOS status 1A,
erum creatinine 1.5 mg/dl, presence of IABP, age 60
ears, use of intravenous inotropic drugs, Caucasian ethnic-
ty, body weight 70 kg, and pulmonary capillary wedge
ressure (PCWP) 20 mm Hg. The presence of ICD on
he day of listing was associated with more favorable
utcomes. Hospitalization on the day of listing demon-
trated statistical collinearity with medical urgency status,
nd therefore it was removed from the final model.
utcomes of the waiting list: UNOS status 2 candi-
ates. Overall, the majority (58%) of 30,978 UNOS status
candidates listed from 1990 to 2005 underwent HT after
he median waiting time of 12.6 months, 17.1% died on the
aiting list, and the remaining 18.7% patients were either
emoved from transplant waiting lists because of improve-
ent (6.3%), deterioration of condition (3.2%), or other
ne-Year Outcomes of the Waiting List in UNOS Status 1 and Statu 1990 to 1994, II  1995 to 1999, and III  2000 to 2005: U.S.
Table 3 One-Year Outcomes of the Waiting List in UNOS Status 1I  1990 to 1994, II  1995 to 1999, and III  2000 to
UNOS Status 1
Era I
(n  4,541)
(%)
Era II
(n  6,087)
(%)
Transplant 60 64.9
Death 25.6 20.4
Removed: improvement 0.1 2.0
Removed: worsening 3.2 2.0
Ongoing 1 yr 4.5 7.7
Ongoing 1 yr 6.6 2.8
NOS  United Network of Organ Sharing.
ultivariable Analysis of Risk Factors for Deathith n 2 Months After List ng of UNOS Status 1andidates for Heart Transplant ti n: U.S. Scientificegistry for T ansplant Recipients: Years 2000 to005 (n  5,451)
Table 4
Multivariable Analysis of Risk Factors for Death
Within 2 Months After Listing of UNOS Status 1
Candidates for Heart Transplantation: U.S.
Scientific Registry for Transplant Recipients:
Years 2000 to 2005 (n  5,451)
Risk Ratio (95% CI) p Value
Mechanical ventilation 2.13 (1.68–2.71) 0.001
Failed heart transplant 2.0 (1.41–3.00) 0.001
Valvular CM 1.93 (1.17–3.19) 0.01
UNOS status 1A 1.92 (1.57–2.35) 0.001
Serum creatinine 1.5 mg/dl 1.77 (1.47–2.12) 0.001
IABP 1.63 (1.29–2.06) 0.001
Age at listing 60 yrs 1.42 (1.16–1.74) 0.001
Intravenous inotropes 1.41 (1.14–1.75) 0.002
Caucasian ethnicity 1.39 (1.13–1.72) 0.002
Body weight 70 kg 1.35 (1.11–1.64) 0.002
PCWP 20 mm Hg 1.29 (1.07–1.54) 0.006
ICD 0.79 (0.65–0.96) 0.001oI  confidence interval; CM  cardiomyopathy; other abbreviations as in Table 2.easons (9.2%), or were ongoing at the time of study (5.6%).
t the end of the follow-up period, 46.2% of patients
emained listed as UNOS status 2, 31.7% were upgraded to
NOS status 1, and 22% were made temporarily inactive.
ne-year outcomes on the waiting list in UNOS status 2
andidates stratified by the eras of listing are shown in Table 3.
ras of listing and HT in UNOS status 2 candidates. The
alculated probability of HT within 1 year from listing of
NOS status 2 candidates censored at the time of removal
rom the waiting list because of death or other reasons was
2.8%, 44.3%, and 49.2% in eras I, II, and III, respectively
p  0.001). The corresponding median time to HT
nitially increased from 10.8 to 15.4 months in eras I and II
nd then decreased to 12.4 months in era III (p  0.001).
ras of listing and survival on the waiting list of UNOS
tatus 2 candidates. The 1-year survival on the waiting list
f UNOS status 2 candidates censored at the time of
emoval from the waiting list because of transplant or other
easons increased from 81.8% to 85% to 89.4% in eras I, II,
nd III (p  0.001), as illustrated in Figure 2B. The 1-year
urvival of UNOS status 2 patients who remained on the
aiting list and did not undergo HT improved from 65% to
2.1% to 81.4% of those listed in eras I, II, and III (p 
.001), whereas for those who underwent HT, survival from
he day of listing until death after HT increased from 89.8%
o 91.8% to 92.5% of those listed in eras I, II, and III (p 
.001), as illustrated in Figure 3B.
redictors of death within 2 months of listing in UNOS
tatus 2 candidates. The results of multivariable analysis of
isk factors for death on the waiting list within 2 months in
,937 UNOS status 2 candidates listed in the years 2000 to
005 are shown in Table 5. Sixteen percent of 8,231 UNOS
tatus 2 candidates were excluded from this analysis because
f the lack of information on the presence of ICD on the
ay of listing or assessment of renal function and hemody-
amics. The following risk factors were identified as inde-
endent predictors of early death: restrictive cardiomyopa-
hies, use of intravenous intoropic drugs, congenital heart
isease, failed HT, secondary causes of dilated cardiomypa-
hy, serum creatinine 1.5 mg/dl, and PCWP 20 mm
g. Blood group B was associated with more favorable
Candidates for Heart Transplantation Across Eras:tific Registry for Transpl t Recipients (n  48,982)
Status 2 Candidates for Heart Transplantation Across Eras:
5: U.S. Scientific Registry for Transplant Recipients (n  48,982)
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n this retrospective analysis of the U.S. population of HT
andidates, we show that the survival of patients awaiting
ransplantation has significantly improved during the last 15
ears. The actual survival on the waiting list censored at
ime of transplantation or removal from the list increased for
NOS status 1 candidates from 49.5% to 63.3% to 69.0%,
nd for UNOS status 2 candidates from 81.8% to 85% to
9.4% at 1 year from listing in eras I (years 1990 to 1994),
I (years 1995 to 1999), and III (years 2000 to 2005),
espectively.
NOS status 1 candidates for HT. The number of
NOS status 1 candidates has nearly doubled since the
arly 1990s from 4,541 to 7,376 patients listed between eras
and III. Despite the rising number of status 1 candidates,
ransplant organizations were able to accommodate donor
rgans at the rate and within the median time that remained
early unchanged throughout the last 15 years. The prob-
bility of receiving HT by the waiting list survivors re-
ained stable, ranging between 83.5% and 86.8% at 1 year
ith the median waiting time to HT averaging 1.4 to 2.4
onths throughout the study period.
Although the likelihood of receiving HT has not sub-
tantially changed, the 1-year survival of status 1 candidates
n the waiting list has improved by nearly 20% (from 49.5%
o 68.9% between eras I and III). There are 3 possible
xplanations of these observations. First, it is possible that
he allocation of organs was prioritized to higher-risk
andidates, thus leaving on the waiting list patients with
etter prognosis. This may particularly apply to the early
000s, when the 2-tiered medical urgency status 1A and 1B
as introduced (5). Second, it is possible that patients listed
n the recent years were less severely ill. It cannot be
xcluded that in some instances hospitalization in ICU and
nfusion of intravenous inotropes resulted from the desire to
atisfy status 1 criteria. Finally, the described improvements
ultivariable Analysis of Risk Factors for Deathith n 2 Months After List ng of UNOS Status 2andidates for Heart Transplant ti n: U.S. Scientificegistry for T ansplant Recipients: Years 2000 to005 (n  6,937)
Table 5
Multivariable Analysis of Risk Factors for Death
Within 2 Months After Listing of UNOS Status 2
Candidates for Heart Transplantation: U.S.
Scientific Registry for Transplant Recipients:
Years 2000 to 2005 (n  6,937)
Risk Ratio (95% CI) p Value
Restrictive CM* 3.94 (1.92–8.09) 0.001
Intravenous inotropes 2.95 (1.89–4.61) 0.001
Congenital heart disease 2.83 (1.24–6.46) 0.01
Failed heart transplant 2.57 (1.39–4.73) 0.002
Secondary dilated CM† 1.86 (1.12–3.11) 0.02
Serum creatinine 1.5 mg/dl 1.70 (1.20–2.41) 0.003
PCWP 20 mm Hg 1.66 (1.20–2.28) 0.002
Blood group B 0.63 (0.45–0.90) 0.01
Restrictive CM includes the following causes: sarcoidosis, amyloidosis, secondary to radiation,
diopathic and other unspecified. †Secondary causes of dilated CM include the following:
driamycin-induced, post-partum, familial, myocarditis, alcoholic, viral, and other unspecified
auses.
Abbreviations as in Tables 2 and 4.ay have resulted from the advances of medical and device 2herapy for heart failure. An example of this may be the use
f ICD, which significantly increased in early 2000s and was
ssociated with significantly improved survival to HT.
nfortunately, because of the lack of information on the
everity of heart failure and details of pharmacologic and
evice therapies, we were not able to elucidate the specific
easons for these trends from the Registry data.
We further show that, despite the aforementioned im-
rovements, the survival of status 1 candidates continued to
epend on urgent cardiac replacement therapy. More than
ne-half (52.4%) of those listed in the years 2000 to 2005
ied within 6 months without HT. The use of MCS on the
ay of listing as a “bridge” to HT has increased nearly 3-fold
ince the early 1990s (8.4% to 22.8% patients in eras I and
II). Unfortunately, the registry does not collect information
n how many of these patients received MCS after they
ere listed. Given continued high 6-month mortality in this
roup without HT, it is possible that MCS may be
nderutilized in this population. We strongly believe that
eft-ventricular assist device implantation should be consid-
red in all high-risk status 1 candidates who require con-
inuous inotropic support and have expected waiting times
xceeding 2 months because of their body habitus, ABO
roup, or allocation region (8).
To identify status 1 HT candidates who warrant the
ighest priority for allocation and/or consideration for
CS, we sought to identify risk factors for 2-month
ortality among patients listed in the recent years 2000
o 2005. The predictors of early death included markers
f worsening pump failure (UNOS status 1A, mechanical
entilation, inotropic and IABP support, elevation of
CWP 20 mm Hg, and renal dysfunction), certain
tiologies of heart disease (valvular cardiomyopathy or
ailed transplant), and patient demographics (age 60
ears, Caucasian ethnicity, and body weight 70 kg).
he presence of ICD on the day of listing, which in some
enters is successfully used as a “bridge” to transplanta-
ion, appeared to have a significant and favorable impact
n the waiting list outcomes. Hospitalization on the day
f listing, which was one of the most powerful predictors
f death in this analysis, was removed from the final
ultivariable model because of its statistical correlation
ith assigned urgency status. Interestingly, MCS was not
n independent predictor of early mortality among those
isted as UNOS status 1; however, it did confer increased
isk of early death when analyzed in the pooled cohort of
tatus 1 and 2 patients (data not shown). Some of the
forementioned predictors, such as hospitalization, par-
icularly in the ICU, use of inotropic drugs, or MCS and
enal dysfunction, have been previously identified as
rognostics of early death in the German national data of
he pooled status 1 and 2 candidates (9).
NOS status 2 candidates for HT. The number of listed
NOS status 2 candidates has significantly decreased
rom 2,332 to 1,147 patients between the years 1990 and
005, which has led to major shifts on the HT waiting
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September 25, 2007:1282–90 Survival of Candidates for Heart Transplantationist, including significant improvement of the listed-to-
ransplanted patient ratio per year (41% to 77% between
990 and 2005), and allowed distribution of donor hearts
o the growing population of the sicker status 1
andidates.
The 1-year survival of status 2 candidates on the waiting
ist improved throughout the eras by 8% (from 81.8% to
9.4% between eras I and III), which appeared independent
rom the rates of HT performed in this group (the proba-
ility of HT at 1 year ranged 44.5% to 52.9% and the
edian time to HT ranged 10.8 to 15.4 months). Demo-
raphics, etiology, and markers of severity of heart failure
id not substantially change throughout the study period,
ndicating that the improved outcomes most likely repre-
ented advances of heart failure therapy. However, as in the
ase of improved outcomes of status 1 candidates, we were
ot able to elucidate the specific reasons of the improved
urvival of status 2 candidates from the Registry data.
It is important to note that, in the current era of medical
herapy, the 1-year survival of status 2 candidates without
T (81.4%) is approaching outcomes of HT (10). These
bservations raise the question whether early listing is
ustified in all status 2 candidates. Both European (11) and
.S. experiences in adult (12) and pediatric (13) patients
ith advanced heart failure consistently show that status 2
andidates are the least likely to benefit from early HT
nless an upgrade of status occurs (11). Deng et al. (14)
elieve that many status 2 candidates may be “too well” to
ransplant and recently proposed clinical trials to justify
eplacement therapy for these patients.
The proposal to delay listing or divert organs from status
candidates to the sickest patients, however, continues to
enerate much controversy (15,16) because status 2 candi-
ates are not a homogeneous group and their mortality risk
ay vary significantly. In this study, nearly one-fifth of
hose listed in the years 2000 to 2005 did not survive 1 year,
learly proving their need for early HT. Previous analyses
evealed that the condition of 40% of status 2 candidates
isted in the early 2000s worsened and required upgrade to
tatus 1 (15). Although some of these who deteriorate may
e salvaged with MCS, the risks of an emergent procedure
ay not be negligible.
Unfortunately, there are no specific criteria to prospec-
ively identify status 2 candidates at increased risk for
eterioration or death. In this study, risk factors associated
ith death within 2 months from listing as status 2 included
arkers of worsening pump failure (increased PCWP, renal
ysfunction, or use of intravenous inotropes) and certain
tiologies of heart disease (congenital heart disease, restric-
ive heart disease, and secondary dilated cardiomypathy, or
ailed HT). This analysis, however, did not include the
ost powerful predictors of survival in advanced heart
ailure, such as peak oxygen consumption, as well as use
f pharmacologic and device therapies. Future analyses
hould incorporate these factors to allow more accurateisk stratification of status 2 HT candidates in the era of
ontemporary heart failure therapy.
On the final note, it is important to mention that the
uality of life of status 2 candidates was not assessed in this
urvey, and although these patients are now able to achieve
remarkably long survival while awaiting HT, their quality
f life may have remained very poor. Although it is generally
greed that the scarce donor hearts should be distributed
nly to those HT candidates with a proven net-survival
enefit, the quality of life is an important consideration in
he decision of listing status 2 candidates, and the potential
hanges in listing policies should not be restricted to the
urvival data alone.
tudy limitations. The results of this study carry limita-
ions associated with the retrospective analysis of a registry
atabase, the quality of the source data, and the lack of
tandardization associated with multicenter studies, as has
een previously described (17). The causes of death on the
aiting list and specifics of medical and device therapy of
atients awaiting HT were not collected by the Registry.
he calculated survival in this study does not account for
hanges of UNOS status while on the waiting list and may
nderestimate the mortality rates of patients who were
ensored at the time of removal from the waiting list due to
orsening of condition. A small percentage of analyzed
tatus 2 candidates met criteria of UNOS status 1, such as the
upport with intravenous inotropes, IABP, or MCS. This may
epresent erroneous status classification or may reflect the
enter’s intent to not transplant patients immediately. There-
ore, results of this study should be interpreted with caution.
onclusions
n this retrospective analysis of the U.S. population of HT
andidates we show that survival on the waiting list has
ignificantly improved. Despite these improvements, sur-
ival of UNOS status 1 candidates continues to depend on
rgent cardiac replacement. We describe risk factors asso-
iated with 2-month mortality that may help identify those
atients who are at the highest priority for donor heart
llocation and/or consideration for MCS. Better methods of
isk stratification of UNOS status 2 candidates are neces-
ary, as in the current era of medical therapy, early listing
ay not be justified in all of these patients.
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